Calfactant Intratracheal: A Lung Surfactant for Neonates
Calfactant intratracheal is a medication used to treat respiratory distress syndrome (RDS) in premature infants. It belongs to a class of medications called lung surfactants.
What is RDS?
RDS is a serious lung condition that affects premature babies. Their lungs are not fully developed, and they lack enough surfactant. Surfactant is a natural substance that lines the inside of the lungs and helps them expand and contract easily during breathing. Without enough surfactant, the air sacs in the lungs (alveoli) can collapse, making it difficult for the baby to breathe.
How does Calfactant intratracheal work?
Calfactant intratracheal replaces the missing natural surfactant in the lungs of premature babies. This helps to:
- Keep the air sacs (alveoli) open during breathing
- Improve lung function
- Reduce the work of breathing for the baby
- Increase oxygen levels in the blood
How is it administered?
Calfactant intratracheal is a liquid medication that is administered directly into the baby's lungs through a thin tube (endotracheal tube) inserted through the mouth or nose. This procedure is typically performed in the Neonatal Intensive Care Unit (NICU) by a healthcare professional.
Important considerations:
- Calfactant intratracheal is a prescription medication and should only be used under the supervision of a healthcare professional.
- The dosage and frequency of administration will vary depending on the individual baby's needs and response to the medication.
- Potential side effects of Calfactant intratracheal can include coughing, wheezing, and low blood oxygen levels. These are usually temporary and mild but should be monitored by healthcare professionals.